HUMA — $1 biotech with a Phase 3 readout in 10 days, 22% short float, and a director just bought the open market

Alright, this is the one I've been waiting on. Locked catalyst, hard date, and the chart's a coiled spring. Writing it up before June 11 so nobody says I posted after the move.

**Humacyte (HUMA) : $1, $240M cap.** They make lab-grown human blood vessels. Already FDA-approved for one use (Dec 2024). But the real trade is the next indication, and the data drops in **10 days.**

**The catalyst:** V012 Phase 3 readout, hemodialysis : **June 11, live at the Vascular Annual Meeting in Boston.** Not "sometime this quarter." A hard, public, on-stage date. The clock is running.

**Why this thing is loaded:**

* **A director bought shares on the open market May 20** — Form 4, public record. Insiders buy their own stock for exactly one reason, and it's 3 weeks before a Phase 3 readout. Read into that what you want.
* The earlier Phase 3 already crushed it in the female subgroup at **p<0.0001.** V012 is the confirmatory study in that exact group. The hard part may already be done.
* They dropped **5.5-year durability data two weeks before** the readout. Nobody does a victory lap right before data they think will flop.
* **Short interest \~22% of float, \~9 days to cover, borrow rates climbing.** Good data into that = forced shorts buying on top of the move. You know what that looks like.

**The math if the data hits:** stock's at $1 with a clean catalyst and a loaded short setup. A good readout puts a 2x in play, and if the squeeze fires it runs further. The asymmetry from $1 is the whole point.